Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 31
1999 25
2000 64
2001 114
2002 163
2003 204
2004 239
2005 253
2006 273
2007 271
2008 297
2009 297
2010 310
2011 337
2012 344
2013 383
2014 333
2015 355
2016 294
2017 287
2018 246
2019 130
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

4,581 results
Results by year
Filters applied: . Clear all
Page 1
The bone remodelling cycle
Kenkre JS and Bassett J. Ann Clin Biochem 2018 - Review. PMID 29368538 Free article.
The key signalling pathways controlling osteoclastic bone resorption and osteoblastic bone formation are receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin and canonical Wnt signalling. ...
The key signalling pathways controlling osteoclastic bone resorption and osteoblastic bone formation are receptor activator of nuclear facto …
The Role of Osteoprotegerin and Its Ligands in Vascular Function.
Rochette L, et al. Int J Mol Sci 2019 - Review. PMID 30736365 Free PMC article.
The superfamily of tumor necrosis factor (TNF) receptors includes osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor kappa-B ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). ...
The superfamily of tumor necrosis factor (TNF) receptors includes osteoprotegerin (OPG) and its ligands, which are receptor activator …
Bone and the Immune System
Weitzmann MN. Toxicol Pathol 2017 - Review. PMID 29046115 Free PMC article.
Physiologically, B cells secrete osteoprotegerin (OPG), a potent anti-osteoclastogenic factor that preserves bone mass. However, activated T cells and B cells secrete pro-osteoclastogenic factors including receptor activator of Nuclear factor-kappaB (NF-kB) ligand (RANKL), Interleukin (IL)-17A, and tumor necrosis factor (TNF)-α promoting bone loss in inflammatory states such as rheumatoid arthritis. ...
Physiologically, B cells secrete osteoprotegerin (OPG), a potent anti-osteoclastogenic factor that preserves bone mass. However, acti …
Orthodontic tooth movement: The biology and clinical implications
Li Y, et al. Kaohsiung J Med Sci 2018 - Review. PMID 29655409 Free article.
Key regulators of inflammation and tissue turnover include secreted factors like RANK ligand and osteoprotegerin, transcription factors such as RUNX2 and hypoxia-inducible factor, cytokines, prostaglandins, tissue necrosis factors, and proteases, among others. ...
Key regulators of inflammation and tissue turnover include secreted factors like RANK ligand and osteoprotegerin, transcription facto …
The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases.
Rochette L, et al. Pharmacol Ther 2018 - Review. PMID 28867452
Members of this family include osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor κB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). ...
Members of this family include osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor κB ligand (RANK …
Preface
Nakanishi T and Kuragano T. Blood Purif 2019. PMID 30943485 Free article.
Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass.
Nozawa S, et al. JCI Insight 2018. PMID 29415886 Free PMC article.
We show that osteoprotegerin (OPG), which is known as a soluble decoy receptor for RANKL, needs to be associated with the osteoblast surface in order to efficiently inhibit RANKL/RANK signaling and that HS serves as a cell surface binding partner for OPG in this context. ...
We show that osteoprotegerin (OPG), which is known as a soluble decoy receptor for RANKL, needs to be associated with the osteoblast …
Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus.
Demková K, et al. Vasa 2018. PMID 29313442 Free article.
BACKGROUND: Osteoprotegerin plays a role in the development of several bone diseases. In addition, osteoprotegerin may contribute to the development of vascular disease. ...Serum osteoprotegerin was measured using ELISA. RESULTS: The mean osteoprotegerin level was significantly higher in patients with PAD in comparison to patients without PAD (18.2 ± 1.0 vs. 13.1 ± 2.0 pmol/L, p = 0.014). ...
BACKGROUND: Osteoprotegerin plays a role in the development of several bone diseases. In addition, osteoprotegerin may contrib …
4,581 results
Jump to page
Feedback